乌鸦传媒

The investigational combination of avutometinib (a dual RAF/MEK inhibitor) and defactinib (a FAK inhibitor) achieved very high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer, according to mid-stage trial data presented at the International Gynecologic Cancer Society annual meeting.

Susana Banerjee, MBBS, PhD, of the Royal Marsden NHS Foundation Trust in London, discusses why she hopes the phase II RAMP 201 trial will help usher in a new standard for low-grade serous ovarian cancer.

Following is a transcript of her remarks:

We're very encouraged by these interim results, and what that's done is lead to the selection of the combination of avutometinib and defactinib as the go-forward regimen in patients with recurrent low-grade serous ovarian cancer. And this is based on the response rates that I've reported in previously treated recurrent low-grade serous ovarian cancer, regardless of the KRAS mutation status, and the manageable safety profile so far with relatively low rates of dose reductions and discontinuation.

So we presented the initial interim results, we will present when we have data from more women enrolled into this study. And the key next step is going forward with a phase III randomized clinical trial. And I very much hope that the regulatory authorities recognize this activity in a rare form of ovarian cancer, where our current approved therapies have lower activity.

So we obviously need more results from this clinical trial and also going forward with further clinical trials. But I very much hope that together, working together globally with patients of low-grade serous ovarian cancer, we may be able to set a new standard of care.